Avalon GloboCare Corp. (NASDAQ:CHGA) Shares Shorted: Short Interest Up 156.5% in September

Posted by Lindsey Winhoffer on Oct 13th, 2026

Avalon GloboCare Corp. (NASDAQ:CHGA – Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 85,127 shares, an increase of 156.5% from the September 15th total of 33,188 shares. Currently, 9.1% of the company’s stock are short sold. Based on an average daily trading volume, of 3,006,731 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, Avalon GloboCare currently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on CHGA

Avalon GloboCare Stock Down 4.3%

Shares of NASDAQ CHGA traded down $0.09 during midday trading on Tuesday, reaching $2.01. 19,380 shares of the company’s stock traded hands, compared to its average volume of 360,737. The company has a market cap of $2.25 million, a price-to-earnings ratio of -0.15 and a beta of -0.08. The stock’s 50 day simple moving average is $3.31 and its 200-day simple moving average is $5.90. Avalon GloboCare has a one year low of $1.79 and a one year high of $47.60.

Avalon GloboCare (NASDAQ:CHGA – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.80) EPS for the quarter.

About Avalon GloboCare

(Get Free Report)

Avalon GloboCare Corp. is a biotechnology company focused on developing cell-based and regenerative medicine technologies. Its work has included cellular immunotherapies, exosome-based products and other platforms intended to support the treatment of cancer and other serious medical conditions.

The company has also pursued activities involving cell and gene therapy development, biobanking and related laboratory services. Avalon GloboCare has described its business as spanning research, product development and potential commercialization through collaborations and strategic partnerships.

Avalon GloboCare was founded in the United States and has historically been associated with operations in New Jersey.